HIV & AIDS

Dec 1, 2014
2 min read

DID YOU KNOW?

People living with HIV globally

35.3 million people living with HIV worldwide
47% of people living with HIV worldwide are women
1.6 million AIDS-related deaths

New HIV cases around the globe in 2012

2.3 million people diagnosed with HIV
6,300 new HIV infections a day
260 000 new HIV infections among children
95% are in low- and middle-income countries

Figures obtained UNAIDS

HIV is a highly variable virus which mutates very readily. This means there are many different strains of HIV, even within the body of a single infected person.

Based on genetic similarities, the numerous virus strains may be classified into types, groups and subtypes.

What is the difference between HIV-1 and HIV-2?

There are two types of HIV, HIV-1 and HIV-2. Both transmitted by sexual contact, through blood, and from mother to child. However, HIV-2 is not transmitted as easyly as HIV-1, and the period between infection and ilness is longer in HIV-2.

The predominant HIV virus in the world is HIV-1. This is the virus people generally refer to when they talk about HIV.

What are the treatment options?

Currently antiretroviral drugs are used. This drugs were designed to use against the subtype B. This antiretroviral drugs may be effective against other subtypes as well. Nevertheless some subtypes may develop resistance to certain drugs, that is why ist is important to research alternative cures.

What alternatives do we have?

Nanotechnology offers opportunities to re-explore biological properties of known antimicrobial compounds by manipulation of their sizes. Such is the case with nano silver colloidal in size. Silver has long been known for its antimicrobial properties, but its medical applications declined with the development of antibiotics.

In a study by the Department of Microbiology from the Autonomous University of Nuevo Leon, Mexico, it was determined that the mode of antiviral action of silver nanoparticles against HIV-1 most commonly known as HIV, is done by the binding of the silver nanoparticles to gp120 in a manner that prevents CD4-dependent virion binding, fusion, and infecticity, acting as an effective virucidal agent against cell-free virus (laboratory strains, clinical isolates, T and M tropic strains, and resistant strains) and cell-associated virus. Besides, silver nanoparticles inhibit post-entry stages of the HIV-1 life cycle.

Their conclusions?

That these properties make them a broad-spectrum agent not prone to inducing resistance that could be used preventatively against a wide variety of circulating HIV-1 strains.

So Remember

When you buy Colloidal Silver from us, you are helping research how nanoparticles of silver colloidal in size can help fight against HIV.

Click here to buy laboratory colloidal silver and contribute to researching a cure.